e-ISSN: Pending
Negative / Null Result Report

Acute and chronic dosing of the GABA A alpha 2,3 selective agonist BAER-101 do not alter behavior but may impact auditory-evoked EEG responses in adults with fragile X syndrome

DeStefano L; Kim H; Erickson C; Pedapati E; Dominick K; Shaffer R; Wink L; Schmitt L · 2025 · Preprint

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract (excerpt)

Abstract Background: Fragile X syndrome (FXS) is characterized by sensory hypersensitivity and neural hyperexcitability linked to GABAergic dysfunction. BAER-101, formerly known as AZD7325, is a positive allosteric modulator of GABA A…

Excerpt shown for reference under fair use — read the full paper at the publisher.

Read full paper at publisher

Hosted by the publisher — may require access.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: Europe PMC · DOI 10.21203/rs.3.rs-8123031/v1